|Adjuvant Therapy for Gastric Carcinoma Patients in the Past 15 Years|
|Ken Shimada and Jaffer A. Ajani|
|Abramson Cancer Center of the University of Pennsylvania|
| Last Modified: November 1, 2001
Reviewers: Li Liu, MD
IntroductionIn 1998, gastric cancer was the 9th leading cause of cancer related death in the United States and the second leading cause in the world. The symptoms and/or signs of gastric cancer are generally nonspecific and the majority of patients present with advanced disease. Routine screening for gastric cancer is generally not performed in western countries because of the low prevalence of the disease. When the tumor is respectable, curative surgery is the mainstay of treatment. Adjuvant therapies have been investigated extensively for more than 30 years. This report by Drs. Shimada and Ajani is a comprehensive review of the role of adjuvant therapy for this disease.
MethodAll randomized studies since 1984 were reviewed.
DiscussionThe routine use of adjuvant therapy for patients with gastric carcinoma is difficult to justify. Further investigation using novel anticancer agents with unique mechanisms of action, such as angiogenesis inhibitors, metalloproteinase inhibitors, antibodies to oncogenes, or gene therapy, are warranted.